Reliance Industries Shares Fall
Reliance Industries Shares Fall: Reliance Industries posted its highest-ever quarterly profit, yet its shares fell by 3% after Q1 FY25 earnings were announced. Investors appeared concerned about weak performance in its oil-to-chemicals segment and margin pressures, despite overall strong numbers.
Image: Mint
Reliance Shares Drop After Record Q1 Profit: What Went Wrong?
Strong Earnings, Weak Stock Response
On Friday, Reliance Industries reported its highest-ever consolidated net profit of ₹21,243 crore for the first quarter of FY25. However, the market reacted unexpectedly. The stock dipped by 3% in early trade, surprising many analysts and investors.
This drop in share price came despite an 11% year-on-year jump in profit, mainly driven by robust growth in the consumer-facing digital and retail segments.
Pressure on Oil-to-Chemicals Segment
The key reason for the stock’s fall lies in the performance of the oil-to-chemicals (O2C) business. Once Reliance’s cash cow, the segment saw muted growth, with analysts citing lower refining margins and weak petrochemical demand as concerns.
Additionally, the EBITDA (earnings before interest, tax, depreciation, and amortization) margin for O2C fell marginally, which raised red flags for short-term investors.
Jio & Retail Continue to Shine
Reliance Jio and Retail delivered impressive numbers. Jio Platforms recorded a net profit of ₹5,466 crore, while Reliance Retail posted a 11.7% YoY jump in net revenue.
These segments continue to show strong growth potential, driven by digital expansion and increased store footprint. Yet, it wasn’t enough to offset market nervousness regarding the O2C vertical.
Why Did the Stock Fall?
While the profit numbers looked great on paper, the stock market focuses on future outlooks and key segment-wise performance. Analysts noted that the weak margin outlook in core segments like O2C could impact earnings in the upcoming quarters.
Moreover, the stock had already run up significantly ahead of earnings, leaving little room for surprise-driven upside.
Read More..- Anthem Biosciences Lists at ₹825, Gains Over 20% on Market Debut
Analyst Commentary
Brokerages like CLSA and Morgan Stanley remained cautious. While they applauded the diversified growth, they also flagged risks in cyclical segments and suggested a ‘neutral’ stance due to limited near-term triggers.
